Our partner Bernardo da Costa e Silva spoke to SBT News about the Oncoclínicas case, which is one of the most closely watched corporate disputes in the Brazilian capital markets and may reach a conclusion this Tuesday (25 August).
The CVM is due to rule today on whether the US investment firm Centaurus Capital will be required to launch a takeover bid for Oncoclínicas shares. Market estimates suggest the transaction could cost around R$ 6.5 billion.
The case involves Centaurus, which claims to have been an investor in the company since before Oncoclínicas went public in 2021, and shareholders who view transactions carried out between 2024 and 2025 as a change in shareholding capable of triggering the so-called ‘poison pill’ – a clause that obliges anyone reaching a 15 per cent stake to make an offer to buy the shares of other investors at a premium.
The asset management firm Latache, advised by our partner and which supports the launch of the takeover bid, held 14.54 per cent of Oncoclínicas prior to the capital increase in November 2025.
In the article, Bernardo explains the case and provides further details. Watch in full.